NasdaqGS:PGENBiotechs
Precigen (PGEN) Is Up 16.3% After Papsimios-Fueled Return To Profitability And Broad Payer Coverage
In the second quarter of 2026, Precigen, Inc. reported revenue of US$54.98 million, net income of US$20.07 million, and diluted earnings per share from continuing operations of US$0.05, a sharp turnaround from the prior year’s loss-making period.
This profitability was driven largely by rapid uptake of Papsimios, supported by expanded payer coverage to about 315 million US lives and seven-year FDA market exclusivity for adult recurrent respiratory papillomatosis.
Next, we will examine how...